Physician profile
Benjamin P Yu
NPI 1972617546
$14,607.40
in general payments reported to CMS, 2019-2025
19 companies · $580 in 2025
The $580 reported for 2025 was more than what a typical Psychiatry provider received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $13K · 2020: $62.10 · 2022: $121 · 2023: $562 · 2024: $752 · 2025: $580.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,894.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,893.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ironshore Pharmaceuticals INC. | $10,941.83 | 2019-2020 | |
| Tris Pharma INC | $1,889.15 | 2019-2025 | Dyanavel Xr, Onyda Xr |
| Otsuka America Pharmaceutical, INC. | $362.27 | 2019-2025 | Rexulti |
| Vanda Pharmaceuticals INC. | $258.14 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $173.25 | 2019 | |
| Allergan, INC. | $168.16 | 2019 | |
| Neurocrine Biosciences, INC. | $155.02 | 2023-2024 | Ingrezza |
| Sunovion Pharmaceuticals INC. | $121.06 | 2019 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $98.27 | 2022 | |
| Neos Therapeutics, Lp | $88.07 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $75.35 | 2019-2020 | |
| Lundbeck LLC | $57.20 | 2019 | |
| Neuronetics, INC. | $55.99 | 2019 | |
| Indivior INC. | $49.85 | 2019 | |
| Shire North American Group INC | $37.56 | 2019 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alkermes, INC. | $22.89 | 2022 | |
| Merck Sharp & Dohme LLC | $20.53 | 2020 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $19.86 | 2019 | |
| Arbor Pharmaceuticals, INC. | $12.95 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Benjamin Yu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.